Skip to content
value.today
BioPorto A/S logo

BioPorto A/S

BIOPOR.CO
$118 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
15
Wikidata

BioPorto A/S in brief

BioPorto A/S is a listed company in the Diagnostics and Research industry, based in Denmark. It was founded in 1917. Its last known market value was $118 M (January 2024); there is no current figure. It employs about 15 people. Its shares trade under the symbol BIOPOR.CO (Copenhagen).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

BioPorto A/S timeline

2 events, 1917–2016
  1. 1917
  2. 🏁
    · approximate
    Founded
  3. 2016
  4. •
    Legal Entity Identifier issued
    LEI 5299004SWFL5JAN4W830 registered.

Events of BioPorto A/S from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$48 M$96 M$143 M$191 M20202021202220232024

World rank over time

▼ down 657 places since 2020
2020-01-01: #19929#19,92920202021-01-01: #15999#15,99920212022-01-07: #21750#21,75020222022-12-25: #20968#20,96820222023-07-30: #23575#23,57520232024-01-05: #20586#20,5862024

Rank in Denmark: #84 (Jan 2020) · #73 (Jan 2021) · #84 (Jan 2022) · #74 (Dec 2022) · #93 (Jul 2023) · #75 (Jan 2024)

Balance sheet

Total assets
$16 M
Total liabilities
$4 M
Total equity
$12 M

As of June-2026

Mutual funds holding BioPorto A/S#

2 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
Mutual funds holding BioPorto A/S
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP51,729$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP21,781$0 M—<0.01%no changeJul 31, 2026

As of Jul 31, 2026

BioPorto A/S: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in DKK millions; per-share figures in DKK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BioPorto A/S: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue403631292423
Cost of revenue9.912119.99.29.9
Gross profit302520191513
Research and development503425353028
Selling and marketing273019211721
General and administrative393636423328
Operating income−86−75−61−82−65−64
Interest and finance income0.52.51.01.22.50.0
Interest expense and finance costs2.10.81.11.21.03.2
Income before tax−88−74−61−82−64−67
Income tax−5.5−5.5−4.9−5.6−6.7−5.3
Net income including minority interests−82−68−56−76−57−62
Earnings per share, basic-0.18-0.17-0.16-0.24-0.21—
Earnings per share, diluted——-0.16-0.24-0.21—
Balance sheet
Cash and cash equivalents5560668246108
Receivables9.48.22.32.87.26.9
Inventory9.24.63.82.62.73.2
Current assets85848210164125
Property, plant and equipment1.52.10.91.6——
Right-of-use (leased) assets4.86.61.32.91210
Other intangible assets0.10.30.50.81.01.2
Non-current assets8.2127.57.21716
Total assets93969010981140
Current liabilities262025312531
Lease liabilities (non-current)4.07.84.37.4108.0
Non-current liabilities4.07.84.37.4118.4
Total liabilities302830383539
Retained earnings−433−361−320−264−222−167
Total equity6368607046101
Total liabilities and equity93969010981140
Shares outstanding———0.30.3—
Cash-flow statement
Depreciation and amortization2.52.42.74.04.3—
Share-based compensation−0.6−0.91.47.6−1.05.3
Cash from operating activities−77−84−55−52−65−36
Capital expenditure0−0.4−0.0−0.4−0.1−1.3
Intangible assets bought———−0.1−0.3−0.2
Cash from investing activities1.31.2−0.3−0.5−0.4−1.5
Debt repaid———−0.3−0.2−0.2
Shares issued77————147
Cash from financing activities727541891.1127
Exchange-rate effect on cash−0.90.2−0.40.61.5−0.1
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2025

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
BioPorto A/S🇩🇰$118 M———
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Balance sheet:
As of June-2026
Profile updated:
Nov 15, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BioPorto A/S? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BioPorto A/S's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BioPorto A/S? Suggest a correction